Oblique Therapeutics announces an agreement with leading animal health company
Stockholm, Sweden – December 9, 2024 – Oblique Therapeutics AB (“Oblique”) announces an agreement with a leading animal health company.
Oblique Therapeutics has entered into an agreement with a leading animal health company to apply the AbiProt® technology to generate antibodies to a high-value target.
“This is a high-value target aimed for use within animal health. As the monoclonal market for animal health has seen tremendous growth in the last years and is expected to grow to over USD 2 billion in five years, more companies are entering this field of use. We believe that our technology can make a difference for this segment as well as in human health, which is proven by our previous collaborations we have within human therapeutics”, said Olof Larsson, CSO of Oblique Therapeutics
The full details of this agreement are not disclosed but it includes an option for additional targets.
About Oblique Therapeutics
Oblique Therapeutics is a biotech company focussing on developing novel therapeutic technologies for the treatment of serious diseases, in particular chronic pain, but also other conditions. The company uses groundbreaking technologies and innovative research to identify and develop antibody based drug candidates.
For further information, please contact: Christer Nordstedt CEO, Oblique Therapeutics AB
E-post: Christer.Nordstedt@obliquet.com